Introduction JAK inhibitors, such as tofacitinib (Xeljanz) and baricitinib (Olumiant), are oral medications used to treat rheumatoid arthritis (RA). They target Janus kinase (JAK) pathways to reduce inflammation. While effective, they have raised safety concerns. In fact, the FDA has

Continue Reading5 JAK Inhibitor Side Effects You Can’t Ignore if You Have Rheumatoid Arthritis